Inozyme Pharma, Inc. (INZY) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K	10-K	S-1/A
Revenues	0.0	0.0	0.0	0.0	8.1
Revenue growth				-100.0%
Cost of goods sold	0.0	0.0	0.0	0.0	11.6
Gross profit	0.0	0.0	0.0	0.0	-3.5
Gross margin					-43.1%
Selling, general and administrative [+]	20.8	18.9	10.5	4.6	3.5
General and administrative	20.8	18.9	10.5	4.6	3.5
Research and development	47.8	37.7	46.5	16.2
Other operating expenses					4.6
EBITDA [+]	-67.9	-56.0	-56.8	-20.7
EBITDA growth	21.4%	-1.5%	174.2%	78.8%
EBITDA margin					-143.1%
Depreciation and amortization	0.7	0.7	0.2	0.1
EBIT [+]	-68.7	-56.6	-57.0	-20.8	-11.6
EBIT growth	21.2%	-0.7%	174.2%	79.5%
EBIT margin					-143.1%
Interest income	1.9	0.2	0.4	1.1	0.3
Interest income	1.9	0.2	0.4	1.1	0.3
Other income (expense), net	-0.3	-0.2	0.2	0.0	4.3
Pre-tax income	-67.1	-56.6	-56.4	-19.7	-7.0
Income taxes	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-67.1	-56.6	-56.4	-19.7	-7.0
Net margin					-86.0%

Basic EPS [+]	($1.78)	($2.40)	($5.11)	($16.67)	($6.63)
Growth	-26.1%	-53.0%	-69.3%	151.5%
Diluted EPS [+]	($1.78)	($2.40)	($5.11)	($16.67)	($6.63)
Growth	-26.1%	-53.0%	-69.3%	151.5%

Shares outstanding (basic) [+]	37.8	23.6	11.0	1.2	1.1
Growth	60.3%	113.5%	832.8%	12.6%
Shares outstanding (diluted) [+]	37.8	23.6	11.0	1.2	1.1
Growth	60.3%	113.5%	832.8%	12.6%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.